Page last updated: 2024-12-06

4-chloro-7-nitrobenzofurazan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Chloro-7-nitrobenzofurazan: A benzofuran derivative used as a protein reagent since the terminal N-NBD-protein conjugate possesses interesting fluorescence and spectral properties. It has also been used as a covalent inhibitor of both beef heart mitochondrial ATPase and bacterial ATPase. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-chloro-7-nitrobenzofurazan : A benzoxadiazole that is 2,1,3-benzoxadiazole which is substituted at position 4 by chlorine and at position 7 by a nitro group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID25043
CHEMBL ID1743207
CHEBI ID78878
SCHEMBL ID41754
SCHEMBL ID16305393
MeSH IDM0014530

Synonyms (74)

Synonym
EU-0033246
4-chloro-7-nitrobenzo-2-oxa-1,3-diazole
STK728793
UPCMLD0ENAT5654999:001
nbd chloride
benzofurazan, 4-chloro-7-nitro-
7-chloro-4-nitrobenzo-2-oxa-1,3-diazole
10199-89-0
nsc228140
7-chloro-4-nitrobenzofurazan
4-chloro-7-nitrobenzofurazan
nbd-c 1
1-chloro-4-nitrobenzoxadiazole
nsc-228140
SHOKAT-UPDATE-COMP17
4-chloro-7-nitro-2,1,3-benzoxadiazole
NCHEMBIO866-COMP17
2,1,3-benzoxadiazole, 4-chloro-7-nitro-
7-chloro-4-nitrobenz-2-oxa-1,3-diazole
nbd-chloride
brn 0614212
4-nitro-7-chlorobenzofurazan
nbf-cl
einecs 233-496-4
chloronitrobenzoxadiazole
nsc 228140
4-chloro-7-nitrobenzofurazan, 98%
4-chloro-7-nitrobenzo[c][1,2,5]oxadiazole
nbd-cl
4-chloro-7-nitrobenz-2-oxa-1,3-diazole
AKOS000121286
chebi:78878 ,
CHEMBL1743207 ,
eqf2794ire ,
unii-eqf2794ire
BBL011971
4-chloro-7-nitrobenzo[c]1,2,5-oxadiazole
FT-0618144
7-nitro-4-chlorobenzofurazan
7-chloro-4-nitro-2,1,3-benzoxadiazole
4-chloro-7-nitro-2,1,3-benzooxadiazole
7-nitrobenzo-2-oxa-1,3-diazol-4-yl chloride
SCHEMBL41754
4-chloro-7-nitro 2,1,3-benzoxadiazole
7-chloro-4-nitro-benzofurazan
4-chloro-7-nitro-benzofurazan
SCHEMBL16305393
DTXSID2064995
AM85450
J-100055
J-610037
4-chloro-7-nitro-benzoxa[1,3]diazole
4-chloro-7-nitrobenzofurazane
4-chloro-7-nitro-2,1,3-benzoxadiazole #
4-chloro-7-nitro-benzo[c][1,2,5]oxadiazole
CS-7530
AC-24649
mfcd00005808
sr-01000596972
SR-01000596972-1
4-chloro-7-nitrobenzofurazan, bioreagent, suitable for fluorescence, >=97.0% (hplc)
AS-64042
H11879
Z104495364
HY-D0042
4-chloro-7-nitrobenzo-2,1,3-oxadiazole
Q229939
nbd chloridenbd chloride
bdbm50523948
: 4-chloro-7-nitro-1,2,3-benzoxadiazole
SY011187
EN300-21329
AKOS040744095
PD063905

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Four-hydroxynonenal is toxic to cultured neurons and to the brain of experimental animals."( Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity.
Lovell, MA; Markesbery, WR; Xie, C, 1998
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
" This method was successfully applied to a pharmacokinetic study after oral administration of a dose (150 mg) of ranitidine."( A sensitive and rapid determination of ranitidine in human plasma by HPLC with fluorescence detection and its application for a pharmacokinetic study.
Tuncel, M; Ulu, ST, 2012
)
0.38
" This method was applied in pharmacokinetic studies of bisoprolol preparations in healthy volunteers."( An HPLC method for the determination of bisoprolol in human plasma and its application to a pharmacokinetic study.
Aydoğmuş, Z; Ulu, ST, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" EPI-MBs+mAb combined with therapeutic ultrasound significantly promoted the MM CSC apoptosis compared with EPI, EPI-MBs alone or EPI-MBs+mAb without ultrasound exposure."( Inhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells.
Di, W; Dou, J; Gu, N; He, X; Li, M; Shi, F; Wu, S; Yang, F; Zhang, Y, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Co-delivery of liposome-encapsulated drug and synthetic short-chain glycosphingolipids (SC-GSLs) significantly improved drug bioavailability by enhancing intracellular drug uptake."( C8-glycosphingolipids preferentially insert into tumor cell membranes and promote chemotherapeutic drug uptake.
Ciceri, D; Contreras, FX; Cordeiro Pedrosa, LR; Eggermont, AM; Goñi, FM; Koning, GA; Steurer, B; ten Hagen, TL; van Cappellen, WA; Verheij, M, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" To explain sigmoidal dose-response curves, a two-site model is already sufficient."( Interaction of cholinergic ligands with the purified acetylcholine receptor protein. I. Equilibrium binding studies.
Maelicke, A; Prinz, H, 1983
)
0.27
" The proposed procedure was successfully applied to the determination of ramipril in both tablet dosage form and in plasma."( Use of 7-fluoro-4-nitrobenzo-2-oxo-1,3-diazole (NBD-F) for the determination of ramipril in tablets and spiked human plasma.
Al-Majed, AA; Al-Zehouri, J, 2001
)
0.31
"A simple kinetic procedure is described for the determination of atenolol in its dosage forms."( Kinetic spectrophotometric determination of atenolol in dosage forms.
Al-Ghannam, SM; Belal, F,
)
0.13
" The proposed methods were successfully applied for the determination of dothiepin hydrochloride in bulk powder and in capsule dosage form."( Kinetic spectrophotometric methods for the determination of dothiepin hydrochloride in bulk and in drug formulation.
Taha, EA, 2003
)
0.32
"Two sensitive, simple and specific methods based on spectrophotometry and reversed-phase HPLC with fluorimetric detection are described for the determination of lisinopril in dosage forms as well as in spiked human plasma using solid phase extraction (SPE) procedures."( Determination of lisinopril in dosage forms and spiked human plasma through derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) followed by spectrophotometry or HPLC with fluorimetric detection.
El-Ashry, SM; El-Emam, AA; El-Sherbiny, DT; Hansen, SH; Moustafa, MA, 2004
)
0.32
" The suggested procedures could be used for the determination of the above mentioned drugs in pure and dosage forms as well as in the presence of their degradation products."( Spectrofluorimetric and spectrophotometric stability-indicating methods for determination of some oxicams using 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD-Cl).
Fattah, Lel-S; Salama, NN; Taha, EA, 2006
)
0.33
" The procedure was favorably applied for determination of certain pharmaceutical dosage forms containing the studied drugs."( Utility of NBD-Cl for the spectrophotometric determination of some skeletal muscle relaxant and antihistaminic drugs.
El-Hay, SS; El-Henawee, MM; Ragab, GH; Saleh, HM, 2007
)
0.34
" The method was applied successfully to the determination of this drug in pharmaceutical dosage form."( Spectrophotometric and spectrofluorimetric methods for the determination of pregabalin in bulk and pharmaceutical preparation.
Onal, A; Sagirli, O, 2009
)
0.35
"A highly sensitive and simple spectrofluorimetric method has been developed and validated for the determination of the antidepressant fluvoxamine (FXM) in its dosage forms and plasma."( Spectrofluorimetric determination of fluvoxamine in dosage forms and plasma via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole.
Abdine, HH; Al-Rayes, LI; Amer, SM; Darwish, IA, 2009
)
0.35
"A sensitive and simple spectrofluorimetric method has been developed and validated for the determination of the antidepressant paroxetine HCl (PXT) in its dosage forms."( Spectrofluorimetric determination of paroxetine HCl in pharmaceuticals via derivatization with 4-chloro-7- nitrobenzo-2-oxa-1,3-diazole (NBD-Cl).
Belal, F; El-Enany, N; Elmansi, H; Walsh, M, 2011
)
0.37
" The methods were successfully applied for the determination of the studied drugs in pharmaceutical dosage forms with excellent recovery."( Utility of 4-chloro-7-nitrobenzofurazan (NBD-CI) for the Spectrophotometric and spectrofluorometric determination of several antihistamine and antihypertensive drugs.
Abd, el-HS; Colyer, CL; Hassan, WS; Shalaby, A,
)
0.52
" The methods were successfully applied for the determination of this drug in pharmaceutical dosage form."( Development of sensitive spectrofluorimetric and spectrophotometric methods for the determination of duloxetine in capsule and spiked human plasma.
Önal, A; Sagirli, O; Toker, SE, 2014
)
0.4
" This approach was effectively employed to evaluate the content of 6-aminocaproic acid in laboratory prepared dosage form with average percentage recovery of 100."( Benzofurazan -based fluorophore for the spectrofluorimetric determination of 6-Aminocaproic acid: Application to spiked human plasma and urine.
Anwer, EF; Derayea, SM; Nour El-Deen, DAM; Omar, MA, 2022
)
0.72
" Herein, a green and highly sensitive spectrofluorimetric method was developed for the determination of aripiprazole in pharmaceutical dosage form and plasma matrix."( Application of a nucleophilic substitution reaction for spectrofluorimetric determination of aripiprazole in pharmaceutical dosage form and plasma matrix; greenness assessment.
Abdullah, O; Alaqel, SL; Alharbi, A; Almalki, AH; Almrasy, AA; Althobaiti, YS; Alturki, MS; Ramzy, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
fluorescent probeA role played by a fluorescent molecular entity used to study the microscopic environment by fluorescence spectroscopy.
fluorochromeA fluorescent dye used to stain biological specimens.
EC 3.6.1.3 (adenosinetriphosphatase) inhibitorAn EC 3.6.1.* (hydrolases acting on acid anhydrides in P-containing anhydrides) inhibitor that interferes with the action of adenosinetriphosphatase (EC 3.6.1.3).
EC 1.4.3.4 (monoamine oxidase) inhibitorAn EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor that interferes with the action of monoamine oxidase (EC 1.4.3.4).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzoxadiazole
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
NAD phosphorylation and transhydrogenation510
NAD phosphorylation and dephosphorylation312
ATP biosynthesis4015

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)141.00000.00403.43889.5100AID1594515
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NPYLR7BAedes aegypti (yellow fever mosquito)EC50 (µMol)4.83000.03902.289918.3000AID1259426
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1594515Inhibition of MERS-CoV papain-like protease using Z-Arg-Leu-Arg-Gly-Gly-AMC as substrate preincubated for 5 mins followed by substrate addition and measured for 10 mins by fluorescence assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,049)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990212 (20.21)18.7374
1990's307 (29.27)18.2507
2000's259 (24.69)29.6817
2010's235 (22.40)24.3611
2020's36 (3.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.37 (24.57)
Research Supply Index6.99 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.09%)5.53%
Reviews10 (0.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,078 (98.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]